Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $0.04.

  • Gyre Therapeutics' EPS (Basic) rose 30000.0% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 10500.0%. This contributed to the annual value of $0.14 for FY2024, which is 10992.91% up from last year.
  • As of Q3 2025, Gyre Therapeutics' EPS (Basic) stood at $0.04, which was up 30000.0% from $0.03 recorded in Q1 2025.
  • Over the past 5 years, Gyre Therapeutics' EPS (Basic) peaked at $1.64 during Q2 2022, and registered a low of -$1.54 during Q4 2023.
  • Over the past 5 years, Gyre Therapeutics' median EPS (Basic) value was $0.01 (recorded in 2024), while the average stood at -$0.24.
  • In the last 5 years, Gyre Therapeutics' EPS (Basic) tumbled by 18214.29% in 2021 and then surged by 35625.0% in 2022.
  • Quarter analysis of 5 years shows Gyre Therapeutics' EPS (Basic) stood at -$0.64 in 2021, then tumbled by 48.15% to -$0.95 in 2022, then tumbled by 62.42% to -$1.54 in 2023, then soared by 100.65% to $0.01 in 2024, then skyrocketed by 300.0% to $0.04 in 2025.
  • Its last three reported values are $0.04 in Q3 2025, $0.03 for Q1 2025, and $0.01 during Q3 2024.